EHR-based approach to boost HBOC genetic testing in at-risk women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study evaluates an EHR-enabled strategy to increase the uptake of hereditary breast and ovarian cancer (HBOC) genetic testing among women aged 21-75 seen in selected NY-Presbyterian primary care clinics. It combines clinician decision-support within the EHR with patient-facing resources, including the RealRisks website, to facilitate informed decision-making about testing. The study builds on prior BNAV and RealRisks work and examines how these tools influence testing rates and provider-patient conversations in routine care. Eligible participants are women without a personal cancer history, who meet a family history risk threshold, and have access to digital devices. The trial aims to identify barriers and facilitators to implementation of decision-support tools in real-world primary care settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Women, age 21-75 years
* Completed Six-Point Scale (SPS) family history screener with a score of 6 or higher.
* Seen in NewYork Presbyterian primary care clinic selected for pilot testing
* No personal history of breast or ovarian cancer
* No prior germline HBOC genetic testing
* English or Spanish-speaking
* Access to a smartphone, tablet, or computer
* Able to provide written, verbal, or online informed consent

Exclusion criteria:

\- Patients who previously participated in the development studies for RealRisks and BNAV.

Where it's running

• Columbia University Irving Medical Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Katherine Crew, MD — Columbia University
• Study coordinator: Research Nurse Navigator
• Email: cancerclinicaltrials@cumc.columbia.edu
• Phone: 212-342-5162

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• Romiplostim N01 plus ATRA for persistent chemotherapy-induced low platelets after remission from gynecologic, breast, or lung cancer

  This trial tests whether adding ATRA to Romiplostim N01 helps people keep a safe platelet count after finishing chemotherapy for certain cancers.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07586826

• CAIX-targeted 18F-T2 PET/CT imaging in solid tumors

  This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07557225

• Preventive removal or staged removal of fallopian tubes and ovaries for women with hereditary ovarian cancer risk

  This project will test whether removing fallopian tubes now and delaying ovary removal, versus standard full removal or close monitoring, reduces ovarian cancer risk and preserves ovarian function in women with BRCA or similar gene changes.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07532434

• RGT-490 for adults with PIK3CA-mutated advanced solid tumors

  This trial will test RGT-490, an oral medicine, in adults whose advanced solid tumors carry a PIK3CA mutation and have progressed after prior therapy.

  Recruiting at 6 sites Phase 1 Regor Pharmaceuticals Inc. · Los Angeles, California and 5 other locations · NCT07524322

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.